Resultado de búsqueda
In adult patients, budesonide/formoterol maintenance and reliever therapy is a safe and simplified approach to asthma management, using a single inhaler, which reduces severe exacerbations and maintains similar daily asthma control at a lower drug load compared with the traditional strategy of ICS/L ….
15 de may. de 2008 · Background: An inhaled corticosteroid (ICS) or an ICS/long-acting beta (2)-agonist (LABA) combination plus short-acting beta (2)-agonist (SABA) as needed for symptom relief is recommended for persistent asthma.
17 de ago. de 2023 · Sigue este enfoque de tres pasos para mantener los síntomas del asma bajo control y prevenir ataques de asma. Escrito por el personal de Mayo Clinic. Los objetivos del tratamiento para el asma son limitar los síntomas, prevenir las crisis asmáticas y evitar los efectos secundarios de los medicamentos para el asma.
Asthma caused by high-molecular-weight chemicals showed a stronger association with rhinitis, conjunctivitis, atopy, and early asthmatic reactions and had a higher risk of airflow limitation, while low-molecular-weight agents were associated with chest tightness, late asthmatic reactions, and increased risk of severe exacerbations.
15 de mar. de 2019 · Asthma exacerbation is recognized clinically based on the following features: progressive increase in shortness of breath, coughing, wheezing, or chest tightness, and a progressive reduction in lung function that requires medical intervention [ 5, 11 ].
asthmatic symptoms. Most widely used is the short-acting β2-agonist, salbutamol. Because a regular schedule of administration four times a day does not improve outcomes, as compared with “as-needed” administration,20 the short-acting β 2-agonists are recommended for use only as needed. Overuse of short-acting β2-agonists is a marker of
Expert commentary: SMART provides greater or equal levels of sustained asthma control than similar or higher fixed doses of ICS/LABA plus short-acting β 2 -agonist (SABA) as needed or higher ICS plus SABA as needed, with lower overall ICS doses and cost.
